<DrugInformationSummary id="CDR0000804890"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Dostarlimab-gxly is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/dostarlimab-gxly">Dostarlimab-gxly</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000780223">dostarlimab-gxly</TerminologyLink><GlossaryLink ref="CDR0000804878">dostarlimab</GlossaryLink><USBrandNames><USBrandName>Jemperli</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>dos-TAR-lih-mab</TermPronunciation><MediaLink ref="CDR0000805968" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000805969" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=095eab9f-545a-4f12-bfb7-19477fb901a5&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Dostarlimab-gxly</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=095eab9f-545a-4f12-bfb7-19477fb901a5&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Dostarlimab-gxly
         is approved to treat adults with:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000444987" dictionary="Cancer.gov" audience="Patient">endometrial cancer</GlossaryTermRef></Strong> that has spread outside the <GlossaryTermRef href="CDR0000046645" dictionary="Cancer.gov" audience="Patient">uterus</GlossaryTermRef> or come back. It is used:<ItemizedList Style="bullet" id="_6"><ListItem>with <GlossaryTermRef href="CDR0000045182" dictionary="Cancer.gov" audience="Patient">carboplatin</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045258" dictionary="Cancer.gov" audience="Patient">paclitaxel</GlossaryTermRef> and then alone</ListItem><ListItem>alone in patients whose cancer is <GlossaryTermRef href="CDR0000789741" dictionary="Cancer.gov" audience="Patient">mismatch repair deficient</GlossaryTermRef> (dMMR) and got worse during or after treatment with <GlossaryTermRef href="CDR0000045841" dictionary="Cancer.gov" audience="Patient">platinum</GlossaryTermRef>-based chemotherapy</ListItem></ItemizedList> </ListItem>
   <ListItem><Strong><GlossaryTermRef href="CDR0000045301" dictionary="Cancer.gov" audience="Patient">solid tumors</GlossaryTermRef></Strong> that are dMMR, have spread or come back,  and got worse during or after other treatment and  cannot be treated with other therapies¹</ListItem></ItemizedList>
  <Para id="_4">¹This use is approved under FDA’s <ExternalRef xref="https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm">Accelerated Approval Program</ExternalRef>. As a condition of approval, <GlossaryTermRef href="CDR0000799146" dictionary="Cancer.gov" audience="Patient">confirmatory trial(s)</GlossaryTermRef> must show that dostarlimab-gxly provides a clinical benefit in these patients.</Para><Para id="_5">Dostarlimab-gxly
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Dostarlimab-gxly</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/780223">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.61">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a621030.html">Dostarlimab-gxly</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.62"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.63">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/endometrial-cancer-durvalumab-pembrolizumab-chemotherapy">More Immunotherapy Options Approved for Treating Endometrial Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/immunotherapy-mismatch-repair-biomarker">A Better Biomarker for Cancer Immunotherapy?</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/immunotherapy-endometrial-cancer-pembrolizumab-dostarlimab">Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/neoadjuvant-immunotherapy-only-treatment">Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer Treatment</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2022/immunotherapy-cancer-biomarker-hla-gene">Cancer Immunotherapies Don’t Work for Everyone: HLA Gene May Explain Why</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors">Immune Checkpoint Inhibitors</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C126799">Find Clinical Trials for Dostarlimab-gxly</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2021-05-24</DateFirstPublished><DateLastModified>2024-12-19</DateLastModified></DrugInformationSummary>
